XRTX - XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity
Story updates
12:11:17 PM UTC
SquawkNews
Investigational New Drug application planned for submission to the U.S. FDA in the fourth quarter of 2026, advancing the Company’s regulatory path toward NDA filing for gout program XRx-026CALGARY, Alberta, Sept. 18, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) NASDAQ…
12:11:50 PM UTC
SquawkNews
XORTX Therapeutics Inc. plans to submit an FDA IND for its XRx-026 gout program in Q4 2026, aiming for an NDA after a planned two-part XRX-OXY-102 trial, subject to funding and positive results.Material DetailsContext by AI AnalystThis is an early regulatory step outlining XORTX’s plan to move XRx…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.